hrs4r
 I want to donate

ANNA ANGONA FIGUERAS

Firma
ANNA ANGONA-FIGUERAS
Position
Investigador/a Consolidat - R3
Established Researchers - R3

Projectes

Codi oficial: 6822ZB3KJ Start date:01/01/2023 Data fi: 31/12/2024 Investigador/a principal: DAVID GALLARDO GIRALT Organisme finançador: AGENCIA DE GESTIO D'AJUTS UNIV. I RECER. Ajuda: 0 €

Publicacions

0

Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis.

HemaSphere, 2023, 7 dx.doi.org/10.1097/HS9.0000000000000818

Barbui T, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Carioli G, Sobas MA, Elli EM, Rumi E, De Stefano V, Lunghi F, Marchetti M, Daffini R, Gasior Kabat M, Cuevas B, Fox ML, Andrade-Campos MM, Palandri F, Guglielmelli P, Benevolo G, Harrison C, Foncillas MA, Bonifacio M, Alvarez-Larran A, Kiladjian JJ, Bolaños Calderón E, Patriarca A, Quiroz Cervantes K, Griessammer M, Garcia-Gutierrez V, Marin Sanchez A, Magro Mazo E, Ruggeri M, Hernandez-Boluda JC, Osorio S, Carreno-Tarragona G, Sagues Serrano M, Kusec R, Navas Elorza B, Angona A, Xicoy Cirici B, Lopez Abadia E, Koschmieder S, Cattaneo D, Bucelli C, Cichocka E, Masternak Kulikowska de Nalecz A, Cavalca F, Borsani O, Betti S, Benajiba L, Bellini M, Curto-Garcia N, Rambaldi A, Vannucchi AM

Second versus first wave of COVID-19 in patients with MPN

Leukemia, 2022, 36, 897-900 dx.doi.org/10.1038/s41375-022-01507-2
0

Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea

CANCER, 2022, 128, 2441-2448 dx.doi.org/10.1002/cncr.34195
0

5 '-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics

EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 109, 755-764 dx.doi.org/10.1111/ejh.13862
0

Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera

ANNALS OF HEMATOLOGY, 2022, 101, 2231-2239 dx.doi.org/10.1007/s00277-022-04963-z
0

Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19

AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97, 470-473 dx.doi.org/10.1002/ajh.26732
0

Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis

BRITISH JOURNAL OF HAEMATOLOGY, 2022, 199, 529-538 dx.doi.org/10.1111/bjh.18440
0

Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera (vol 101, 2231, 2022)

ANNALS OF HEMATOLOGY, 2022, 101, 2819-2820 dx.doi.org/10.1007/s00277-022-05005-4
0

Breakthrough infections in MPN-COVID vaccinated patients

BLOOD CANCER JOURNAL, 2022, 12, 154-154 dx.doi.org/10.1038/s41408-022-00749-8

Alvarez-Larrán A, Angona A, Andrade-Campos M, Soledad Noya M, Teresa Gómez-Casares M, Cuevas B, Caballero G, García-Hernández C, García-Gutiérrez V, Palomino A, Ferrer-Marín F, Isabel Mata-Vázquez M, Moretó A, Magro E, Murillo I, Manuel Alonso-Domínguez J, María Guerra J, Guerrero L, María Raya J, Pérez-Encinas M, Carreño-Tarragona G, Fox L, Pastor-Galán I, Bellosillo B, Hernández-Boluda JC

Cytoreductive treatment in patients withCALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia

BRITISH JOURNAL OF HAEMATOLOGY, 2021, 192, 988-996 dx.doi.org/10.1111/bjh.16988

Formulari de contacte

About IDIBGI!

menu